Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 2 records in total 2
    records per page




    In silico immune infiltration profiling reveals the role of naïve B cells in lung tissues of COVID-19 patients

    Authors: Yi-Lin Chiu; Yi-Ying Wu; Sheng-Huei Wang; Chih-Hsien Wu; Li-Chen Yen; Hsing-Fan Lai; Chin-Liang Ho

    doi:10.21203/rs.3.rs-37877/v1 Date: 2020-06-25 Source: ResearchSquare

    COVID-19 caused by SARS-CoV-2 has rapidly spread to more than 160 countries worldwide since 2020. Despite the tremendous efforts and resources spent around the world trying to explore antiviral drugs, there is still no effective clinical treatment for COVID-19. Approximately 15% of COVID-19 cases progress to pneumonia MESHD pneumonia HP, patients with severe pneumonia MESHD pneumonia HP may die from acute respiratory distress HP syndrome MESHD (ARDS). In addition, further pulmonary fibrosis MESHD pulmonary fibrosis HP from SARS-CoV-2 infection MESHD causes ARDS that often leads to irreversible impairment of lung function. If the mechanisms by which SARS-CoV-2 infection MESHD primarily cause immune responses or immune cell infiltration can be identified, it is possible to alleviate or prevent severe lung damage by modulating the infiltration and activation of specific immune cells to mitigate excessive immunity response.The extent to which subsets of immune cells are significantly altered in the lung tissue of COVID-19 patients remains unclear. This study applied the CIBERSORT method to comprehensively evaluate the immune infiltration landscape in lung tissues of COVID-19 patients, and further compared with the one from lung tissue of patients with idiopathic pulmonary fibrosis MESHD pulmonary fibrosis HP (IPF). We found several immune cell subtypes; particularly naïve B cells are highly infiltrated in COVID-19 group. A comparison of functional gene set analysis revealed that non-differentiated naïve B cells may be the main cause of the overactive humoral immune response. We further compared several specific COVID-19 cases receiving therapies targeting B cells and found that appropriate suppression of naïve B cells might be a new strategy to alleviate severe symptoms of COVID-19.

    THE MUC5B PROMOTOR POLYMORPHISM ASSOCIATES WITH SEVERE COVID-19

    Authors: Coline H.M. van Moorsel; Joanne J van der Vis; Claudia Benschop; Henk J.T. Ruven; Marian Quanjel; Jan C Grutters

    doi:10.1101/2020.05.12.20099333 Date: 2020-05-16 Source: medRxiv

    Background Diversity in response to exposition to severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) is common and may be related to the innate immune response. The mucin MUC5B is an important component of the innate immune response and expression levels are associated with the MUC5B promoter polymorphism, rs35705950. The high expressing T-allele of rs35705950 is an accepted risk allele for a non-infectious aging lung disease MESHD called idiopathic pulmonary fibrosis MESHD pulmonary fibrosis HP (IPF). However, given the theory of trade-offs in aging lung disease MESHD and the importance of high expression for an adequate immune response, we hypothesize that the T-allele is protective against severe coronavirus disease MESHD 2019 (COVID-19). Methods We collected demographics, radiology, survival data and MUC5B rs35705950 allele status for 108 patients requiring hospitalisation for COVID-19 at St Antonius Hospital in The Netherlands. For comparison of allele frequencies and allele carriership with a white control cohort, the patient cohort was divided in a white (n=83) and non-white cohort. Results The patients had a median age TRANS of 66 years and consisted predominantly of males TRANS (74%) and 23 patients (21%) died. The T-allele frequencies of rs35705950 in white patients was 0.04 which was significantly lower than the T-allele frequency of 0.10 in white controls (p= 0.02). Moreover, comparison of the number of carriers TRANS and non- carriers TRANS of the T allele showed that only 8.4% of patients carried the T-allele versus 18% of controls (p=0.029; OR= 0.41, CI=0.19-0.94). Conclusions The MUC5B rs35705950 promoter polymorphism associates with COVID-19. The risk allele (T) for IPF is protective against the development of severe COVID-19 disease MESHD. This is a further example of a trade-off between optimal expression levels in the respiratory system which associates with aging diseases MESHD. However, these results require further investigation.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.